Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 93.35% is 19% above its 5-year average of 78.56%, near the high end of its 5-year range (-118.64%–99.80%).
0.51% below its 12-month average of 93.83%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 93.24%.
GROSS MARGIN
93.35%
GROSS MARGIN AVG TTM
93.83%
GROSS MARGIN AVG 3Y
84.33%
GROSS MARGIN AVG 5Y
78.56%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.51%
CURRENT VS 3Y AVG
+10.70%
CURRENT VS 5Y AVG
+18.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 373 covered companies
CURRENT VS SECTOR MEDIAN
+99.94%
vs the sector median at left
BridgeBio Pharma, Inc.
Market Cap
$12.95B
Gross Margin
93.35%
TTM Avg
93.83%
3Y Avg
84.33%
5Y Avg
78.56%
Market Cap
$12.89B
Gross Margin
21.85%
TTM Avg
27.90%
3Y Avg
28.49%
5Y Avg
28.39%
Market Cap
$13.19B
Gross Margin
98.30%
TTM Avg
98.34%
3Y Avg
98.50%
5Y Avg
98.50%
Market Cap
$12.52B
Gross Margin
30.08%
TTM Avg
33.76%
3Y Avg
35.72%
5Y Avg
36.84%
Market Cap
$12.17B
Gross Margin
12.38%
TTM Avg
12.93%
3Y Avg
14.91%
5Y Avg
16.18%
Market Cap
$12.00B
Gross Margin
95.71%
TTM Avg
68.63%
3Y Avg
54.72%
5Y Avg
59.42%
Market Cap
$14.16B
Gross Margin
90.18%
TTM Avg
86.45%
3Y Avg
83.14%
5Y Avg
81.21%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | 93.35% | 93.83% | 84.33% | 78.56% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 21.85% | 27.90% | 28.49% | 28.39% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 98.30% | 98.34% | 98.50% | 98.50% |
| Baxter International Inc. (BAX)vs › | $12.52B | 30.08% | 33.76% | 35.72% | 36.84% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.84% | 65.17% | 64.50% | 63.66% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 12.38% | 12.93% | 14.91% | 16.18% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 95.71% | 68.63% | 54.72% | 59.42% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 90.18% | 86.45% | 83.14% | 81.21% |
| DaVita Inc. (DVA)vs › | $11.47B | 31.02% | 29.95% | 30.17% | 30.48% |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 65.77% | 65.28% | 66.17% | 66.85% |
Gross Margin
93.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 93.24% |
| 2026-03-31 | 94.64% |
| 2025-12-31 | 90.00% |
| 2025-09-30 | 94.56% |
| 2025-06-30 | 96.70% |
| 2025-03-31 | 97.74% |
| 2024-12-31 | 64.57% |
| 2024-09-30 | 78.11% |
| 2024-06-30 | 72.42% |
| 2024-03-31 | 99.72% |
| 2023-12-31 | 65.73% |
| 2023-09-30 | 85.38% |
| 2023-06-30 | 63.50% |
| 2023-03-31 | 64.35% |
| 2022-12-31 | 65.40% |
| 2022-09-30 | -118.64% |
| 2022-06-30 | 99.05% |
| 2022-03-31 | 20.43% |
| 2021-12-31 | 87.96% |
| 2021-09-30 | 37.97% |
| 2021-06-30 | 99.80% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 90.65% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
